Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Accured Expenses (2017 - 2026)

Denali Therapeutics has reported Change in Accured Expenses over the past 9 years, most recently at $12.7 million for Q4 2025.

  • Quarterly Change in Accured Expenses rose 547.82% to $12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $465000.0 through Dec 2025, down 85.68% year-over-year, with the annual reading at $465000.0 for FY2025, 85.68% down from the prior year.
  • Change in Accured Expenses was $12.7 million for Q4 2025 at Denali Therapeutics, up from $1.9 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $24.6 million in Q3 2024 and troughed at -$32.2 million in Q2 2023.
  • The 5-year median for Change in Accured Expenses is $2.1 million (2024), against an average of $1.1 million.
  • Year-over-year, Change in Accured Expenses tumbled 649.17% in 2023 and then soared 3249.59% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $7.8 million in 2021, then tumbled by 48.16% to $4.0 million in 2022, then soared by 255.43% to $14.3 million in 2023, then tumbled by 119.86% to -$2.8 million in 2024, then skyrocketed by 547.82% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Change in Accured Expenses are $12.7 million (Q4 2025), $1.9 million (Q3 2025), and -$7.7 million (Q2 2025).